Arix Bioscience PLC (ARIX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013136)
◆英語タイトル:Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013136
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:35
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥57,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥85,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Arix Bioscience PLC (Arix Bioscience), formerly Arix Bioscience Ltd, is a healthcare and life science company. It offers financing and operational and strategic direction for the companies to support their businesses. The company’s expertise spans in various areas which include academic science, clinical and commercial strategy, company operations, venture capital, mergers and acquisitions and corporate finance. Arix Bioscience works in collaboration with universities in the UK, Europe and Australia for providing direct access to the innovative new technologies. It offers its services to both public and private sector companies. The company also has an operational presence in New York, the US. Arix Bioscience is headquartered in London, the UK.

Arix Bioscience PLC (ARIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arix Bioscience PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arix Bioscience PLC, Medical Devices Deals, 2011 to YTD 2017 9
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Autolus Raises USD80 Million in Series C Financing 13
PreciThera Raises USD28.8 Million in Series A Financing 15
Amplyx Pharma Raises USD67 Million in Series C Financing 16
Mitoconix Bio Raises USD20 Million in Series A Financing 18
LogicBio Therapeutics Raises USD45 Million in Series B Financing 19
Harpoon Therapeutics Raises USD45 Million in series B Financing 20
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 21
Artios Pharma Raises USD33.2 Million in Series A Financing 23
OptiKira Raises Funds through Venture Financing 24
Partnerships 25
Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 25
Licensing Agreements 26
Mitoconix Bio Enters into Licensing Agreement with Stanford University 26
Equity Offering 27
Arix Bioscience Completes Underwriter’s Exercise of Over-Allotment Option of IPO for USD142 Million 27
Verona Pharma Raises USD63 Million in Private Placement of Units 28
Arix Bioscience PLC – Key Competitors 31
Arix Bioscience PLC – Key Employees 32
Arix Bioscience PLC – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Sep 04, 2017: Arix Bioscience notes the appointment of Dr Graeme Smith as CSO of Artios Pharma 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arix Bioscience PLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arix Bioscience PLC, Deals By Therapy Area, 2011 to YTD 2017 8
Arix Bioscience PLC, Medical Devices Deals, 2011 to YTD 2017 9
Arix Bioscience PLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Autolus Raises USD80 Million in Series C Financing 13
PreciThera Raises USD28.8 Million in Series A Financing 15
Amplyx Pharma Raises USD67 Million in Series C Financing 16
Mitoconix Bio Raises USD20 Million in Series A Financing 18
LogicBio Therapeutics Raises USD45 Million in Series B Financing 19
Harpoon Therapeutics Raises USD45 Million in series B Financing 20
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 21
Artios Pharma Raises USD33.2 Million in Series A Financing 23
OptiKira Raises Funds through Venture Financing 24
Arix Bioscience, Lead Discovery Center, Max Planck Innovation and University of Leeds Enter into Partnership 25
Mitoconix Bio Enters into Licensing Agreement with Stanford University 26
Arix Bioscience Completes Underwriter’s Exercise of Over-Allotment Option of IPO for USD142 Million 27
Verona Pharma Raises USD63 Million in Private Placement of Units 28
Arix Bioscience PLC, Key Competitors 31
Arix Bioscience PLC, Key Employees 32
Arix Bioscience PLC, Other Locations 33
Arix Bioscience PLC, Subsidiaries 33

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Arix Bioscience PLC (ARIX)-製薬・医療分野:企業M&A・提携分析(Arix Bioscience PLC (ARIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆